Publications

CQ-397 and CQ-414: Antimicrobial activity and spectrum of two fluoroquinolone—cephalosporin, dual-action compounds with carboxamido bonds. by Johnson DM and Jones RN. published in Clin. Microbiol. Infect. 1997; 3 (3): 335-344

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. by Jamjian C, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (2): 454-459

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing. by Jamjian C, Barrett MS and Jones RN published in Diagn, Microbiol, Infect, Dis, 1997; 27 (4): 129-138

Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 Gram-negative bacteria. by Gales AC, Pignatari AC, Jones RN, Baretta M and Sader HS published in Rev. Assoc. Med. Bras. 1997; 43 (2): 137-144

Antimicrobial susceptibility of Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil. by Gales AC, Bolmstrom A, Sampaio J, Jones RN and Sader HS published in Braz. J. Infect. Dis. 1997; 1 (4): 196-203

Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates. by Flynn CM, Kelley CM, Barrett MS and Jones RN published in J. Clin. Microbiol. 1997; 35 (8): 2083-2086

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin. by Erwin ME, Varnam D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 28 (2): 93-100

Multicenter laboratory evaluation of the bioMerieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. by Doern GV, Brueggemann AB, Perla R, Daly J, Halkias D, Jones RN and Saubolle MA published in J. Clin. Microbiol. 1997; 35 (8): 2115-2119

A cluster of serious Escherichia coli infections in a neonatal intensive care unit. by Diekema DJ, Barr J, Boyken LD, Buschelman BJ, Jones RN, Pfaller MA and Herwaldt LA published in Infect. Control Hosp. Epidemiol. 1997; 18 (11): 774-776

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. by Cormican MG and Jones RN published in Antimicrob. Agents Chemother. 1997; 41 (1): 204-211

Avoparcin, a glycopeptide used in animal foods: Antimicrobial spectrum and potency tested against human isolates from the United States. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 241-248

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. by Biedenbach DJ, Schermer IH and Jones RN published in Diagn. Microbiol. Infect. Dis. 1997; 27 (1-2): 1-5

Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1997; 35 (12): 3198-3202

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. by Ballow CH, Jones RN, Johnson DM, Deinhart JA, and Schentag JJ published in Diagn. Microbiol. Infect. Dis. 1997; 29 (3): 173-186

Proposed MIC quality control guidelines for National Committee for Clinical Laboratory Standards susceptibility tests using seven veterinary antimicrobial agents: ceftiofur, enrofloxacin, florfenicol, penicillin G-novobiocin, pirlimycin, premafloxacin, and spectinomycin. by Marshall SA, Jones RN, Wanger A, Washington JA, Doern GV, Leber AL and Haugen TH published in J. Clin. Microbiol. 1996; 34 (8): 2027-2029

Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U- 100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. by Worth S, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 87-91

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. by Jones RN published in Am. J. Med. 1996; 100 (6A): 3S-12S

Critical appraisal of Etest for the detection of fluoroquinolone resistance. by Jones RN, Erwin ME and Croco JL published in J. Antimicrob. Chemother. 1996; 38 (1): 21-25

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (4): 153-161

Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMerieux Vitek System. by Doern GV, Torres BB, Jankins M and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (3): 133-135

False resistance to metronidazole by Etest among anaerobic bacteria investigations of contributing test conditions and medium quality. by Cormican MG, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 117-119

Phenotypic detection of mecA-positive staphylococcal bloodstream isolates: High accuracy of simple disk diffusion tests. by Cormican MG, Wilke WW, Barrett MS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 25 (3): 107-112

Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the Etest ESBL screen. by Cormican MG, Marshall SA and Jones RN published in J. Clin. Microbiol. 1996; 34 (8): 1880-1884

Re-evaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. by Cormican MG, Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 1996; 1 (3): 190-194

Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: Investigation using 510(k) review criteria, recommended by the Food and Drug Administration. by Biedenbach DJ and Jones RN published in J. Clin. Microbiol. 1996; 34 (12): 3214-3217

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1996; 24 (2): 113-116

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. by Baron EJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (3): 141-151

Evaluation of Vitek and API 20S for species identification of enterococci. by Sader HS, Biedenbach D and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (4): 315-319

Evaluation of S1 chromogenic cephalosporin β-lactamase disk assay tested against Gram-positive anaerobes, coagulase-negative staphylococci, Prevotella spp. and Enterococcus spp. by Marshall SA, Sutton LD and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (4): 353-355

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres. by Jones RN, Kehrberg EN and Erwin ME published in Drugs 1995; 49 (Suppl 2): 179-181

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. by Jones RN, Sader HS, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1995; 21 (2): 85-93

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the Etest to recognize glycopeptide-resistant strains. by Jones RN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1995; 21 (2): 95-100

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: A review. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 22 (1-2): 19-33

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. by Jones RN published in J. Chemother. 1995; 7 (Suppl 2): 7-16

Canadian ofloxacin susceptibility study: A comparative study from 18 medical centers. Canadian Ofloxacin Study Group. by Hoban DJ and Jones RN. published in Chemotherapy 1995; 41 (1): 34-38

Multicenter clinical laboratory evaluation of a β-lactamase disk assay employing a novel chromogenic cephalosporin, S1. by Doern GV, Jones RN, Gerlach EH, Washington JA, Biedenbach DJ, Brueggemann A, Erwin ME, Knapp C and Raymond J published in J. Clin. Microbiol. 1995; 33 (6): 1665-1667

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). by Cormican MG, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 51-54

Re-evaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates. by Cormican MG and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (4): 227-230

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1995; 21 (1): 57-60

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes. by Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 1995; 39 (7): 1636-1642

Evaluation of interhospital spread of methicillin-resistant Staphylococcus aureus in Sao Paulo, Brazil, using pulsed-field gel electrophoresis of chromosomal DNA. by Sader HS, Pignatari AC, Hollis RJ and Jones RN published in Infect. Control Hosp. Epidemiol. 1994; 15 (5): 320-323

Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended- spectrum β-lactamase-producing Enterobacteriaceae. by Sader HS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 20 (4): 203-208

Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals. by Murphy SP, Erwin ME and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 20 (1): 49-55

North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group. by Jones RN and Hoban DJ published in Diagn. Microbiol. Infect. Dis. 1994; 18 (1): 49-56

Interpretive criteria for DU-6859a disk diffusion tests using 5- micrograms disks. by Jones RN, Johnson DM and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 18 (2): 125-127

Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards. by Jones RN, Doern GV, Gerlach EH, Hindler J and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 18 (4): 243-249

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: Real or perceived? Fluoroquinolone Resistance Surveillance Group. by Jones RN, Kehrberg EN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1994; 19 (4): 203-215

Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group. by Jones RN, Sader HS and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1994; 20 (2): 93-98

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results. by Jones RN, Sutton LD, Cantrell HF and Lankford RB published in Diagn. Microbiol. Infect. Dis. 1994; 20 (3): 143-149

Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. by Houston AK and Jones RN published in Diagn. Microbiol. Infect. Dis. 1994; 18 (1): 57-59